Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-26T12:29:52.434Z Has data issue: false hasContentIssue false

Serious Adverse Events and the Modafinil Augmentation Study

Published online by Cambridge University Press:  07 November 2014

Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter to the Editor
Copyright
Copyright © Cambridge University Press 2006

References

REFERENCES

1.Thase, ME, Fava, M, DeBattista, C, Arora, S, Hughes, RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2):93102.Google Scholar
1.Fava, M, Thase, ME, DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66:8593.Google Scholar
2.Khan, A, Khan, S, Kolts, R, Brown, WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: Analysis of FDA reports. Am J Psychiatry. 2003;160:790792.CrossRefGoogle ScholarPubMed
3.Ferguson, D, Doucette, S, Glass, KC, et al.Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ. 2005;330:396402.Google Scholar
4.Gunnell, D, Saperia, J, Ashby, D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330:385.CrossRefGoogle Scholar
5.FDA Public Health Advisory. Suicidality in adults being treated with antidepressant medications. Available at: http://www.fda.gov/cder/drug/advisory/SSRI200507.htm. June 30. 2005. Accessed March 17, 2006.Google Scholar